phrykt

Lexicon Pharmaceuticals, Inc. (LXRX): who owns it and who trades it

As of Nov 16, 2026, LXRX insiders reported 9 purchases worth $2.8M in the last 12 months. The largest buyer was Artal Group S.A. (Director), with $2M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Lexicon Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LXRX

148 funds and institutions reported LXRX shares worth $880M at the end of Q2 2026, about 87% of the company. The largest holder is Artal Group S.A. with 41.3%.

Funds and institutions (13F) 87%Everyone else 13%

10 largest owners, by share of the company

Artal Group S.A.41.3%
FMR LLC (Fidelity)12.2%
Siren, L.L.C.10.5%
Sessa Capital IM, L.P.4.5%
BlackRock, Inc.4.1%
Vanguard Capital Management LLC2.3%
Point72 Asset Management, L.P.1.9%
Geode Capital Management, LLC1.5%
State Street Corp1.2%
Vanguard Portfolio Management LLC0.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Artal Group S.A.175.16M41.34%$420M+13%
FMR LLC (Fidelity)51.78M12.22%$124M+15%
Siren, L.L.C.44.30M10.46%$106MNo change
Sessa Capital IM, L.P.18.96M4.48%$45.5M+6%
BlackRock, Inc.17.35M4.09%$41.6M+422%
Vanguard Capital Management LLC9.90M2.34%$23.8M+4%
Point72 Asset Management, L.P.8.25M1.95%$19.8M+6%
Geode Capital Management, LLC6.24M1.47%$15M+97%
State Street Corp4.92M1.16%$11.8M+410%
Vanguard Portfolio Management LLC2.36M0.56%$5.7M+331%
Northern Trust Corp1.97M0.46%$4.7M+298%
Charles Schwab Investment Management Inc1.96M0.46%$4.7M+49%
Sixth Street Partners Management Company, L.P.1.96M0.46%$4.7M–
Vanguard Fiduciary Trust Co1.63M0.39%$3.9M+23%
Citadel Advisors LLC1.60M0.38%$3.8M+46%
Ishara Investments LP1.27M0.30%$3.1M+41%
Millennium Management LLC1.13M0.27%$2.7M-77%
Renaissance Technologies LLC1.13M0.27%$2.7M-30%
Mackenzie Financial Corp963,3540.23%$2.3M+25%
ADAR1 Capital Management, LLC750,0000.18%$1.8MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, LXRX insiders reported $2.8M of open-market purchases and $0 of sales.

Purchases, 12 months
$2.8M
9 trades, 3 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 6, 2026
Filed Nov 9, 2026

Purchases and sales by month

$2.7M$2.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 6, 2026Michael ExtonCEOPurchase30,064$1.66$50KForm 4
Feb 25, 2026Raymond DebbaneDirectorPurchase2,000$1.49$3KForm 4
Feb 23, 2026Raymond DebbaneDirectorPurchase100,000$1.47$147KForm 4
Feb 20, 2026Raymond DebbaneDirectorPurchase100,000$1.48$148KForm 4
Feb 19, 2026Raymond DebbaneDirectorPurchase50,000$1.44$72KForm 4
Feb 18, 2026Raymond DebbaneDirectorPurchase133,688$1.32$176KForm 4
Feb 17, 2026Raymond DebbaneDirectorPurchase76,857$1.31$101KForm 4
Feb 13, 2026Raymond DebbaneDirectorPurchase57,952$1.31$75.9KForm 4
Feb 2, 2026Artal Group S.A. +8DirectorPurchase1.54M$1.30$2MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Artal Group S.A.Director, 10% owner$2M–Feb 2, 2026
Raymond DebbaneDirector$723K–Feb 25, 2026
Michael ExtonChief Executive Officer, Director$50K–Nov 6, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LXRX short interest

Moderate short interest. 5.8% of LXRX shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went down 1%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 25.88M LXRX shares were sold short, 5.8% of the shares outstanding, down 3.1% from the report before. At the average daily volume of 1.84M shares, buying them all back would take about 14.0 trading days (days to cover).

Shares short, % of all shares

5.82%May 15Oct 308.04%

Days to cover

14.0May 15Oct 3015.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202625.88M5.82%-3%1.84M14.0
Oct 15, 202626.70M6.00%+3%2.06M13.0
Sep 30, 202625.83M5.80%-10%4.19M6.2
Sep 15, 202628.79M6.47%-2%2.15M13.4
Aug 31, 202629.49M6.63%-10%2.87M10.3
Aug 14, 202632.75M7.36%-0%3.00M10.9
Jul 31, 202632.83M7.75%+0%2.63M12.5
Jul 15, 202632.73M7.73%+6%2.72M12.0
Jun 30, 202630.78M7.27%+21%6.93M4.4
Jun 15, 202625.43M6.00%-3%2.02M12.6
May 29, 202626.21M6.19%+0%1.91M13.7
May 15, 202626.14M6.17%+10%4.20M6.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Lexicon Pharmaceuticals company events

Lexicon Pharmaceuticals filed 8 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. May 7, 2026ResultsReleased financial results. Filing
  4. May 6, 2026AgreementLexicon Pharmaceuticals, Inc. and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates that provides up to $100 million in borrowing capacity available in three tranches, each maturing in May 2030. Filing
  5. Apr 30, 2026AgreementSigned an important agreement. Filing
  6. Mar 5, 2026ResultsReleased financial results. Filing
  7. Feb 2, 2026AgreementLexicon Pharmaceuticals, Inc. entered into an Underwriting Agreement with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein, relating to a public offering of 32,000,000 shares of the Company’s common stock, par value $0.001 per share. Filing
  8. Jan 29, 2026AnnouncementThe information set forth in Item 2.02 of this Current Report is hereby incorporated in this Item 8.01 by reference. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Lexicon Pharmaceuticals financials

Famous investors that hold LXRX

3 of the 50 well-known investors we track reported holding LXRX in their latest 13F filing. The largest position is Ken Griffin's, worth $2.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.46M$2.7M0.0%-9%
Steve Cohen · Point72 Asset ManagementQ3 2026988,279$1.9M0.0%-88%
Israel Englander · Millennium ManagementQ3 2026786,034$1.5M0.0%-31%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named LXRX in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A15.0%
Nov 5, 2026FMR LLC13G/A15.0%

Questions about Lexicon Pharmaceuticals, Inc. (LXRX) stock

Who owns the most LXRX stock?

The largest reported owner of Lexicon Pharmaceuticals, Inc. (LXRX) is Artal Group S.A., with 41.3% of the company. In total, 148 funds and institutions reported holding LXRX at the end of Q2 2026, together about 87% of the shares. See the largest owners.

Are LXRX insiders buying or selling?

In the last 12 months, LXRX insiders reported 9 open-market purchases worth $2.8M and no sales. The latest trade was on Nov 6, 2026. See every trade.

What is the short interest in LXRX?

As of Oct 30, 2026, 25.88M LXRX shares were sold short, 5.8% of the shares outstanding, down 3.1% from the report before. At the average daily volume of 1.84M shares, buying them all back would take about 14.0 trading days (days to cover). See the history.

Which famous investors hold LXRX?

3 of the 50 well-known investors we track reported LXRX in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $2.7M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.